Global AAV Gene Therapy Injection Market Growth (Status and Outlook) 2026-2032

The global AAV Gene Therapy Injection market size is predicted to grow from US$ 2476 million in 2025 to US$ 13030 million in 2032; it is expected to grow at a CAGR of 27.3% from 2026 to 2032.

AAV gene therapy injection is a biological preparation that contains the adeno - associated virus (AAV) vector. It's designed to deliver specific therapeutic genes into the cells of a patient's body for the treatment of diseases. This injection is a crucial tool in gene therapy and functions through direct injection into human tissues or intravenous infusion. Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus.

United States market for AAV Gene Therapy Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for AAV Gene Therapy Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for AAV Gene Therapy Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key AAV Gene Therapy Injection players cover Avexis/Novartis (Zolgensma), Sarepta Therapeutics (Elevidys), Spark/Roche (Luxturna), PTC Therapeutics (Upstaza), BioMarin (Roctavian), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the “AAV Gene Therapy Injection Industry Forecast” looks at past sales and reviews total world AAV Gene Therapy Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected AAV Gene Therapy Injection sales for 2026 through 2032. With AAV Gene Therapy Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AAV Gene Therapy Injection industry.

This Insight Report provides a comprehensive analysis of the global AAV Gene Therapy Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on AAV Gene Therapy Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AAV Gene Therapy Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AAV Gene Therapy Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AAV Gene Therapy Injection.

This report presents a comprehensive overview, market shares, and growth opportunities of AAV Gene Therapy Injection market by product type, application, key players and key regions and countries.

Segmentation by Type:
scAAV9 Vector
AVV2 Vector
AVV5 Vector
AAVrh74 Vector

Segmentation by Application:
Spinal Muscular Atrophy (SMA)
Ophthalmic Diseases
Hemophilia
Duchenne Muscular Dystrophy (DMD)
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Avexis/Novartis (Zolgensma)
Sarepta Therapeutics (Elevidys)
Spark/Roche (Luxturna)
PTC Therapeutics (Upstaza)
BioMarin (Roctavian)
CSL/uniQure (Hemgenix&Glybera)
Pfizer
Beijing Innovikang (Pipeline)
Suzhou NoJieBeig (Pipeline)
Belief BioMed (Pipeline)

Please note: The report will take approximately 2 business days to prepare and deliver. Show more